<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01213459</url>
  </required_header>
  <id_info>
    <org_study_id>111336</org_study_id>
    <nct_id>NCT01213459</nct_id>
  </id_info>
  <brief_title>Study on the Prevalence of Human Papillomavirus Types in Women &gt;= 15 Years of Age in the Kingdom of Saudi Arabia</brief_title>
  <official_title>An Observational, Epidemiological Study on the Prevalence of Human Papillomavirus (HPV) Types in Women &gt;= 15 Years of Age, in the Kingdom of Saudi Arabia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This study aims to determine the prevalence of human papillomavirus (HPV) and to assess the
      HPV type distribution among women &gt;= 15 years of age, attending routine gynaecological
      examination in the Kingdom of Saudi Arabia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of any human papillomavirus deoxyribo nucleic acid and of different types of human papillomavirus (including multiple infections) among women undergoing cervical screening.</measure>
    <time_frame>At least 12 months from the date of subject enrolment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of any human papillomavirus deoxyribo nucleic acid and of different types of human papillomavirus (high risk and low risk) among women of different age strata undergoing cervical screening.</measure>
    <time_frame>At least 12 months from the date of subject enrolment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavioural risk factors such as age at first marriage and age at first pregnancy (assessed through administration of a behavioural questionnaire).</measure>
    <time_frame>At least 12 months from the date of subject enrolment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of awareness of human papillomavirus and its relation to transmission and to causation of cervical cancer.</measure>
    <time_frame>At least 12 months from the date of subject enrolment</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">420</enrollment>
  <condition>Infections, Papillomavirus</condition>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <description>Women â‰¥15 years of age attending out-patient departments for routine cervical screening in the Kingdom of Saudi Arabia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cervical samples</intervention_name>
    <description>Human papillomavirus detection and typing in cervical samples.</description>
    <arm_group_label>Cohort A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Data collection</intervention_name>
    <description>Questionnaire completion</description>
    <arm_group_label>Cohort A</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Cervical samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Women &gt;=15 years of age attending out-patient departments of primary, secondary or tertiary
        care centers for routine cervical screening, in the Kingdom of Saudi Arabia.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects/Subjects' parents or guardians, who the investigator believes that they can
             and will comply with the requirements of the protocol should be enrolled in the study,

          -  Women &gt;=15 years of age attending a clinic for routine cervical screening,

          -  Written informed consent obtained from the subject and/or subject's parent/guardian.

        Exclusion Criteria:

          -  Referral for abnormal cervical sample at the current visit,

          -  Abundant menstrual bleeding or vaginal discharge not allowing appropriate screening to
             be performed,

          -  No cervical sample provided,

          -  History of hysterectomy,

          -  Known diagnosis of immunosuppression, or patient on immunosuppressives,

          -  Pregnant female &gt;=25 years of age.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Riyadh</city>
        <zip>11211</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2010</study_first_submitted>
  <study_first_submitted_qc>October 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2010</study_first_posted>
  <last_update_submitted>November 21, 2012</last_update_submitted>
  <last_update_submitted_qc>November 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Human papillomavirus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

